Cytosorbents (NASDAQ:CTSO) Announces Earnings Results

Cytosorbents (NASDAQ:CTSO) announced its quarterly earnings results on Wednesday, March 25th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04), Zacks reports. The business had revenue of $9.23 million for the quarter, compared to analysts’ expectations of $9.21 million. Cytosorbents had a negative return on equity of 131.86% and a negative net margin of 22.12%.

Here are the key takeaways from Cytosorbents’ conference call:

• Full‑year revenue was up 4% to $37.1M with record core product sales, driven by double‑digit growth in international direct sales (+13%) and distributor sales (+11.4%) but partially offset by a 10% decline in Germany due to a commercial restructuring.
• Gross margins strengthened to 71% for the year and 74% in Q4, driven by manufacturing efficiencies that support improved profitability and lower production spend going into 2026.
• DrugSorb‑ATR faces regulatory uncertainty after an initial de novo denial, but the appeal found no safety concerns, FDA discussions are ongoing for a targeted resubmission, and the STAR‑T randomized trial was published showing safety and reduced bleeding.
• Management has reduced costs (including a Q4 restructuring), improved operating and adjusted EBITDA losses, and expects operating cash‑flow breakeven in the second half of 2026 while carrying $7.8M in cash as of year‑end.
• Commercial innovations—>100 placements of the standalone PuriFi pump and the new HotSwap cartridge‑exchange—are intended to expand access, enable earlier intervention, and drive incremental recurring disposable cartridge usage.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $0.55 on Thursday. The company has a market cap of $34.32 million, a price-to-earnings ratio of -4.21 and a beta of 1.47. Cytosorbents has a twelve month low of $0.50 and a twelve month high of $1.39. The business has a 50 day moving average price of $0.68 and a 200 day moving average price of $0.74. The company has a quick ratio of 1.71, a current ratio of 2.11 and a debt-to-equity ratio of 1.61.

Institutional Investors Weigh In On Cytosorbents

Hedge funds have recently made changes to their positions in the company. Avenir Corp raised its position in shares of Cytosorbents by 2.9% during the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after acquiring an additional 147,261 shares during the last quarter. Vanguard Group Inc. lifted its stake in Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after buying an additional 79,535 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of Cytosorbents in the 3rd quarter valued at about $161,000. Goldman Sachs Group Inc. grew its stake in shares of Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares in the last quarter. Finally, Citadel Advisors LLC increased its stake in Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Thursday, March 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a report on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.38.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.